The history of chemical sensitivity in America is reviewed from the rst description published by Edgar Allan Poe in 1839, to its rst medical de nition as a symptom of neurasthenia in 1869, its rediscovery as allergic toxemia in 1945, its rede nition in 1987 as multiple chemical sensitivity (MCS), and its overlap in the 1990s with chronic fatigue syndrome, bromyalgia syndrome, and Gulf War syndrome (GWS). More than half of the over 500 peer-reviewed articles on MCS support an organic basis for MCS, whereas less than one-quarter support a psychiatric basis. The same 2:1 difference is seen in the numbers of MCS researchers writing these articles and the number of journals publishing them. A psychogenic interpretation of MCS also is speci cally rejected in the latest formal position statement on the subject, a 1994 consensus of the American Lung Association, American Medical Association (AMA), U.S. Environmental Protection Agency (US EPA), and U.S. Consumer Product Safety Commission (US CPSC) (U.S. Government Printing Of ce 1994-523-217/81322). This and other government recognition of MCS in policy, research, and scienti c conferences are summarized. Dozens of federal, state, and local authorities accept MCS as a legitimate disease and/or disability that deserves reasonable accommodation in housing, employment, and public facilities. Of cial recognition is expected later in 1999 when the U.S. Centers for Disease Control and Prevention (CDC) announces a formal definition of MCS and the federal Interagency Workgroup on MCS releases its long-awaited nal report, 4 years in the making.
HISTORICAL INTRODUCTION
The great debate over the etiology of the syndrome now known as Multiple Chemical Sensitivity (MCS) dates back at least to 1839 when Edgar Allen Poe wrote the rst American description of MCS in "The Fall of House of Usher." Poe describes an unnamed disease af icting Roderick Usher, who "suffered much from a morbid acuteness of the senses; the most insipid food was alone endurable; he could wear only garments of certain texture; the odors of all owers were oppressive; his eyes were tortured by even a faint light; and there were but peculiar sounds, and these from stringed instruments, which did not inspire him with horror." He also hints at a possible cause: an atmosphere that hung about the mansion "which had no af nity with the air of heaven . . . a pestilent and mystic vapor or gas, dull, sluggish, faintly discernible, and leaden-hued." This could well be a description of the highly toxic illuminating gas that was manufactured in the early 1800s from coal and contained 4-6% carbon monoxide and lesser amounts of hydrogen sul de benzene, toluene, and other volatile organic compounds.
Of the 30 speci c symptoms that Poe attributes either to Roderick or his narrator, an average of 27 are recognized today by people who associate the onset of their MCS with a chronic low-level exposure to carbon monoxide and/or leaking propane, whereas fewer than 2 of 30 are recognized by non-MCS controls (Donnay 1999) . Although many of Poe's critics (then and now) assumed that Roderick was a madman who simply imagined all these symptoms, Poe himself-like MCS patients todaystrongly resisted any psychogenic interpretation. When he describes sensory hyperesthesia again in "The Tell Tale Heart" in 1843, he pointedly reminds his readers that what they "mistake for madness is but overacuteness of the senses."
More than 150 years later, this remains the most divisive issue in the debate over MCS: do the symptoms re ect a real physical illness caused by toxic chemical exposures or are they caused only by psychogenic factors and/or an iatrogenic belief system that misinterprets benign exposures as harmful. Fortunately, a great deal more scienti c information about the disorder is now available than in Poe's time.
The syndrome Poe described was not even de ned in American medicine until 20 years after his death, when George Miller Beard (1869) , a New York City neurologist, and Edward Van Deusen (1869), a Michigan insane asylum director, separately published papers suggesting that it should be called neurasthenia for "nervous weakness." They both interpreted the disease as an organic brain disorder which they blamed on the many technological and social stresses of their "modern" era. Beard speci cally noted the negative in uences of the steam engine, telegraph, printing press, and the higher education of women. Although neither they nor any other physician ever considered the possible role of illuminating gas, they clearly recognized the therapeutic bene ts of fresh air and commonly recommended that their neurasthenic patients escape the pestilent "miasmas" of urban areas by going for extended periods to "rest" in less polluted rural areas, such as at the many spas established in this era.
The diagnosis of neurasthenia quickly became one of the most common and fashionable in urban America by 1900. But as no brain or other lesion could be found, its organic etiology was hotly debated and gradually reinterpreted by mainstream medicine as psychiatric. Freud (1895) , for example, blamed it entirely on excessive masturbation. Most signi cantly, medical literature on the diagnosis of neurasthenia and all its many subtypes (sexual, traumatic, cerebral, etc., as referenced in the Index-Catalogue of the Library of the Surgeon General's Of ce) disappeared rapidly after the turn of the century as the use of illuminating gas was phased out.
When Theron Randolph, the "father" of modern environmental medicine, rediscovered the same syndrome in 1945 in asso- ciation with food intolerances, he tried to distinguish it from the long-discredited syndrome of neurasthenia by calling it "allergic toxemia" (Randolph 1945) . He also soon recognized its association with chronic low-level exposure to the various utility gases (also manufactured from coal) that were still used in his day for heating, cooking, and refrigeration (Randolph 1952) . Many competing names for this disorder were introduced in the 1970s: ranging from food and chemical sensitivities (Bell 1975) and chemical hypersusceptibility (Reinhardt 1978) to mass hysteria (Stahl and Lebedun 1974) and mass psychogenic illness (Colligan and Smith 1978) . Only in 1987-148 years after Poe rst described "multi-sensory sensitivity" and 118 years after Beard and Van Deusen rst called it neurasthenia-was the name MCS formally proposed by Mark Cullen of Yale. He de ned MCS as a chronic and otherwise unexplained condition acquired in relation to an environmental exposure, insult, or illness that is characterized by any multiple symptoms in any multiple organs that wax and wane in response to multiple chemical exposures at levels far below those tolerated by the general population or, more precisely (because these levels vary so much among individuals), at levels far below those previously tolerated (Cullen 1987) . Some of the many symptoms, organs, senses, and chemical exposures that have since been reported in association with MCS are shown in Table 1 .
RECOGNITION OF MCS IN MEDICAL LITERATURE
Since 1945, more than 500 articles have been published on MCS by one name or another in the peer-reviewed medical and scienti c literature. This bibliography was compiled over the last 4 years by MCS Referral & Resources from National Library of Medicine holdings and other original sources. It does not include any articles from the Journal of Clinical Ecology, which was controversial and not widely recognized in its day, but it does include position statements adopted by various medical associations since 1986 on the practice of clinical ecology and/or the diagnosis of MCS (Table 2) . As these positions are still cited by those who dismiss MCS as psychogenic (Barrett and Gots 1998) , it is important to note how outdated most of them are: all but one are from 1992 or earlier, whereas more than half the literature on MCS has been published since. The only multi-agency consensus position statement on MCS was adopted jointly in 1994 by the American Lung Association (ALA), American Medical Association (AMA), U.S. Environmental Protection Agency (EPA), and U.S. Consumer Product Safety Commission (CPSC). It stresses that "in cases of claimed or suspected MCS, the current consensus is that complaints should not be dismissed as psychogenic and a thorough workup is essential" (ALA 1994). Those who still dismiss MCS as psychogenic, therefore, are clearly outside this mainstream consensus, which accurately re ects the medical literature on MCS published since 1945.
There are more than twice as many peer-reviewed articles, books, and book chapters that support an organic interpretation of MCS as compared to those supporting a psychogenic or iatrogenic view, and this gap has been consistent for decades. The same 2:1 predominance of organic over psychiatric perspectives is also seen in the number of rst authors, total authors, and journals publishing these ndings (Table 3 ). There is very little overlap among either rst authors in these categories-just 9 to 11% across all columns-showing that few have modi ed their original views of MCS. Among journals and book publishers, the overlap is 20% overall but only 8% among the organic and psychogenic columns, indicating that, like authors, few editors ever publish opposing views of MCS.
Within this literature may be found evidence of numerous abnormal signs and diagnostic tests associated with MCS (Table 4) . Although no single one of these signs or markers has been reported abnormal consistently in all MCS cases, and many such as c Research design papers propose methods for studying various psychogenic and organic hypotheses. These are categorized separately because the studies have not been done.
d The overlap is the percentage by which the row sum exceeds 100%. It shows the percent of authors and journals that have published in more than one of these categories.
TABLE 4
Multiple objective signs and test abnormalities associated with MCS vitamin and mineral de ciencies are common to other disorders, a few are extremely rare. Two such abnormalities normally found in less than 1 in 10,000 of the general population are genetically inherited mast cell and porphyrin metabolism disorders, both of which-very much like MCS-are characterized by multisensory sensitivity and a great diversity of symptoms in response to chemical and other exposures.
The diagnostic tests for these disorders show a relatively unique pattern of abnormality in MCS cases, with results characteristically outside normal ranges but also short of the extremes typically associated with the inherited forms. Heuser and Kent (1996) has reported nding abnormal mast cell biopsies in 80% of MCS clinic patients, whereas a protocol developed with the Mayo Medical Laboratories to screen comprehensively for porphyrin disorders in blood, urine, and stool (Donnay and Ziem 1995) found multiple de ciencies in 88% of those tested (Ziem and McTamney 1997) .
Such high sensitivity, especially when combined with the tests' better than 99.999% speci city in the general population and their etiological consistency with MCS, suggests porphyrin and mast cell biomarkers may be useful in screening and documenting objective abnormalities in MCS cases. Although these biomarkers have not yet been studied together in MCS patients, the most by which they can differ is only 12%, resulting in a high degree of sensitivity and speci city for those who test positive for both (based on laboratory normal reference ranges). Another less speci c biomarker of mastocytosis that may be evaluated more easily is the serum tryptase level, which may be either abnormally high or low but is rarely normal .
A variety of theories have been proposed to explain possible mechanisms of MCS (Table 5) . No well-designed human studies have been carried out to test any of the psychiatric hypotheses (Davidoff and Fogarty 1994) , but, as noted above, signi cant data exist to support the mast cell and porphyrin theories. The most recent hypothesis, that chronic carbon monoxide (CO) poisoning may trigger MCS (Donnay 1998a) , is based on ndings that CO, like nitric oxide, is a neurotransmitter (Verma et al. 1993; Ingi and Ronnett 1995) . It controls sensitization and desensitization to odors, sound, and light and plays a key role in memory, blood vessel tone, gastrointestinal tone, and cardiac function-all of which have been reported abnormal in MCS cases (Bell, Baldwin, and Schwartz 1998a) .
Although the medical literature is divided over these various proposed mechanisms of MCS, there is a remarkable consistency in the prevalence rates of diagnosed and undiagnosed chemical sensitivity found in epidemiological studies of randomly selected adults in New Mexico, North Carolina, and California. These range from 1.9 to 6.3% already diagnosed with MCS or suffering daily, and 15.9 to 33% reporting some degree of chemical sensitivity (Table 6) .
Two studies of Gulf War era veterans by the US CDC show rates of chemical sensitivity among those who were not deployed but are still on active duty in the range of 2 (Fukuda 1998) to 2.6% (Black 1998, personal correspondence), but among those who were deployed, the MCS rates are more than twice as high: from 5 to 5.5%, respectively. Among randomly selected Gulf War era veterans who are no longer on active duty, a study by the Department of Veterans Affairs (DVA) found rates of chemical sensitivity that are almost three times higher: 14.9% in the deployed compared to 4.9% in the nondeployed (Kang et al. 1998 ). The highest MCS rate of all-35.9%-was found in another DVA study of veterans who signed up for the DVA's Gulf War Registry (Fiedler, Kipen, and Natelson 1998) . Unfortunately, neither the Department of Defense nor the DVA has incorporated these research ndings into their clinical protocols. As a result, Gulf War era veterans are still not being routinely screened, diagnosed, compensated, or treated for MCS.
Even higher prevalence rates have been reported in civilian studies of chronic fatigue syndrome (CFS) clinic patients-67% of whom had MCS (Buchwald and Garrity 1994)-and bromyalgia (FM) clinic patients-56% of whom did so (Slotkoff, Radulovic, and Clauw 1997) . The only study of these overlaps among MCS clinic patients found 47% with all three, 41% with only MCS and CFS, 10% with MCS alone, and just 2% with MCS and FM (Donnay and Ziem 1999b) .
A 1999 Consensus on MCS, signed by over 30 physicians and researchers, attempts for the rst time to establish a formal de nition of MCS for use in clinical practice (Bartha et al. 1999) . It requires all six of the following:
1. The symptoms are reproducible with repeated chemical exposure. 2. The condition is chronic.
3. Low levels of exposure [lower than previously or commonly tolerated] result in manifestations of the syndrome. 4. The symptoms improve or resolve when the incitants are removed. 5. Responses occur to multiple chemically unrelated substances. 6. Symptoms involve multiple organ systems.
RECOGNITION OF MCS IN GOVERNMENT POLICY
The United States federal government rst began funding MCS-related "chemosensory" research into smell and taste disorders in 1968, through the National Institute of Health (NIH) National Institute on Neurological Disorders and Stroke. In 1987, this research funding-provided mostly to scientists working closely with fragrance and avor industries-was spun off into a new agency, the NIH's National Institute on Deafness and Other Communication Disorders (NIDCD). In scal year 1997 alone, NIDCD's Chemical Senses Branch spent $28.6 million dollars on chemosensory research, which is more than the MCS spending of all other federal agencies combined (personal communication with Rochelle Small 1998).
Although most of these funds go for research into disorders involving the loss of smell and/or taste, rather than the hypersensitivity seen in MCS, NIDCD has made important contributions to basic research into the neurophysiology and genetics of olfaction. It funded the Johns Hopkins University study, for example, that rst reported CO was a neurotransmitter of olfaction (Verma et al. 1993 ), a clearly relevant nding that is still not widely known to either toxicologists or MCS specialists.
Government interest in MCS as an indoor air quality issue grew out of US EPA's own experience with an epidemic of Sick Building Syndrome (SBS) and MCS, that began in 1987 1991, 1993, 1994, 1995, b with the remodeling of its Washington DC headquarters known as Waterside Mall. Hundreds of employees were affected by the end of 1988 and dozens can no longer work in the building, but only a few are being accommodated with alternative work assignments and/or telecommuting arrangements (Ziem and McTamney 1997) . In response, US EPA researchers conducted the largest occupational study ever done of SBS and MCS, surveying nearly 4000 employees in this and two other smaller EPA buildings and 3000 controls working in the Madison building of the Library of Congress. They found approximately one-third (29 to 33%) of the occupants in each building, including the controls, complained of being "especially sensitivity to chemical fumes" and that this was "signi cantly related to health factors more often than any other [of 48] variables" (Wallace et al. 1993 ), although those working in the Library of Congress appeared to have been sensitized by mold from books rather than by any type of remodeling exposures such as the new carpet installation that rst triggered symptoms at Waterside Mall.
US EPA also commissioned the National Research Council to convene a scienti c conference on MCS in 1991, which was just the rst of a dozen on MCS cosponsored by eight federal agencies over the next 8 years (Table 7) . Unfortunately, few of their many policy or research recommendations have been adopted. The latest "research planning conference"-this one on the health impact of chemical exposures during the Gulf War-was held February 28 to March 2, 1999. The cosponsors, the US NIH, CDC, and the Agency for Toxic Substances and Disease Registry (ATSDR), speci cally promised Congress in 1998 that the one goal of this conference would be to develop a formal de nition MCS to standardize future research (Eisenberg 1998) . A consensus de nition was proposed at the conference and published independently by 34 MCS physicians and researchers (Bartha 1999) .
Also expected later in 1999 is the nal MCS report of the federal government's Interagency Workgroup on MCS. This 4year effort was initiated by US EPA and cochaired by ATSDR, the government's lead agency on MCS policy up to now, and the CDC's National Center for Environmental Health, which at the time had no experience with MCS but which has since been involved in two studies of Gulf War Veterans as discussed above. Other agencies included in the eight-member workgroup are the Departments of Defense, Energy, and Veterans' Affairs, the National Institute for Occupational Health and Safety, and the National Institute for Environmental Health Sciences, the largest funder of MCS-related research in the 1990s aside from the US NIDCD, which was not included (see Table 7 , footnote "a").
Unfortunately, the Workgroup's efforts were undermined by numerous procedural problems (Donnay 1998b ):
1. All its meetings were conducted in secret, few minutes were kept, and no input was solicited along the way from patients, doctors, or the many other federal, state and local government authorities that also support MCS research and/or have adopted MCS policies ( attorneys, and insurers to oppose recognition of MCS. Although the Workgroup supposedly terminated Mitchell's involvement shortly after this con ict was brought to its attention, the Workgroup also decided against disclosing either Mitchell's ESRI af liation or his key role as rst author in their nal draft, which lists him only as a "consultant." 3. although the Workgroup later solicited comments from its member agencies and a dozen outside experts, there is no written record-as is usually required-documenting how these comments were addressed and most, in fact, appear to have been ignored.
The most recent draft released for public comment in August 1998 re ects these problems and is more notable for all it omits than the sparse and misleading information it contains. As documented in the comments led by MCS Referral & Resources (Donnay 1998b ): less than one-third of the MCS literature published since 1945 is reviewed, including less than half that published in just the last 5 years; although all eight agencies have been involved in MCS research (this supposedly is why they were invited to join the Workgroup) , only ATSDR reveals any information about either the funding or results of any of its MCS research, but even these data are incomplete; and no information is provided on the MCS research funding, ndings, or policies of at least 14 other federal government authorities that were not included, such as the legal memorandum issued by the Social Security Administration stipulating "that it recognizes multiple chemical sensitivity as a medically determinable impairment" (Stern and Goodwin 1997) .
In response to a request from MCS Referral and Resources, the Governing Council of the American Public Health Association unanimously adopted a "late breaking" resolution (98-LB-5) at its annual meeting in November 1998 calling on the Interagency Workgroup to provide all this missing information in its nal report so that-as originally intended-it may serve as a useful guide to public health policy making and research planning.
SUMMARY
The chronic disorder now known as MCS-characterized by multiple symptoms in multiple organs in response to multiple previously tolerated chemical exposures-has been recognized in medical literature by one name or another for 130 years. More than half of the over 500 peer-reviewed articles published since 1945 support an organic interpretation, whereas less than one-quarter support a psychiatric view. A psychogenic etiology is speci cally rejected in the 1994 consensus statement of the ALA, AMA, US EPA, and US CPSC.
The 2 to 6% prevalence of diagnosed MCS found in the general population of New Mexico and California ranks the disorder among the top 10 to 20 most common chronic illnesses in the United States. MCS clearly is already widely recognized by physicians in clinical practice, but the nding that so many more who complain of symptoms remain undiagnosed-10% in California and 15% in New Mexico-shows that much more professional outreach and education of physicians needs to be done. This is a role the US NIH should take on, just as it has begun to educate physicians about chronic fatigue syndrome and bromyalgia, two equally variable disorders with which MCS has been reported to overlap by as much as 88% and 49%, respectively (Donnay and Ziem 1999) . US Department of Defense and Veterans' Affairs physicians also need to be taught how to diagnose and treat MCS, as the disorder is truly epidemic among Gulf War veterans, whose relative risk of developing the disorder is two to three times that of their nondeployed brethren.
Since the late 1980s, dozens of federal and state government agencies have recognized MCS in one fashion or another and adopted policies to accommodate their own employees and/or others with MCS. Nine federal agencies and three states have together spent millions on MCS research and sponsored 13 MCS conferences. A consensus de nition of MCS nally emerged from the last in March 1999, signed by 34 physicians and researchers.
Although many sectors of the chemical industry still oppose recognition of MCS in medicine, law, and government policy for liability reasons, some consumer product manufacturers are simultaneously seeking to pro t from MCS by promoting less toxic, unscented, and undyed products for this growing sector of the consumer market.
Industrial toxicologists can make an important contribution by screening new chemicals, drugs, and other products carefully to identify and eliminate, or at least minimize, the use of sensitizers and irritants that provoke symptoms in MCS and the many disorders with which it overlaps: from extremely rare mastocytosis and porphyria to common migraine, allergy, and asthma. More research is also needed on the effects of chronic carbon monoxide poisoning-especially from dichloromethane exposures-on the senses, especially hearing, olfaction and vision, whose habituation is controlled by carbon monoxide and abnormally hypersensitive in most MCS cases.
